Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus

Summary

To investigate the efficacy of using antiviral therapy in third trimester of pregnancy to reduce mother-to-infant HBV transmission, and to access the safety of such treatment for mothers and infants.

Timeline

Start

2010-12-29

Primary completion

2020-12-31

Completion

2021-12-31

Publications

• Wen WH, Liu CJ, Lai MW, Tsai MC, Mu SC, Lee CL, Cheng SW, Hsu JJ, Lin YC, Hu JJ, Shu CT, Lin MW, Yang YJ, Hu KC, Chien RN, Ko SC, Chen YC, Shih JC, Lee CN, Chen HL, Chang MH. Peripartum ALT Flares Predict Earlier Postpartum HBeAg Clearance in Highly Viremic HBV-Infected Women: A Long-term Follow-up Study. JHEP Rep. 2026 Jun 25:101936. doi: 10.1016/j.jhepr.2026.101936. Online ahead of print.
• Chen HL, Lee CN, Chang CH, Lai MW, Tsai MC, Mu SC, Liu CJ, Shih JC, Wen WH, Hu RT, Huang CP, Hu KC, Chen CP, Lee CL, Chien RN, Chang KC, Hsu HY, Lee CC, Ni YH, Chang MH. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes. Liver Int. 2024 Jun;44(6):1422-1434. doi: 10.1111/liv.15873. Epub 2024 Mar 8.

Drugs

Indications